ACHN:NSD-Achillion Pharmaceuticals, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 6.76

Change

0.00 (0.00)%

Market Cap

USD 0.95B

Average Target Price

USD 6.30 (-6.80%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Company Website : http://www.achillion.com

Address : 300 George Street 06511,New Haven,USA

Employees : 56

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.59

52 Week High : 207.48

52 Week Low : 137.50

Shorted Shares : 8,603,331

200 Day Moving Average : 5.56

Shorted Shares Previous Month : 8,832,343

50 Day Moving Average : 6.76

Short Percentage : 12.00%

Shares Held by Institutions : 88%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 N/A
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 N/A
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 1,000,000.00 N/A
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing ACHN

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.11% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.11% 88% B+ 93% A
Trailing 12 Months  
Capital Gain 129.15% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 129.15% 93% A 97% A+
Trailing 5 Years  
Capital Gain -33.46% 54% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.46% 51% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -2.58% 37% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.58% 36% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 65.74% 37% F 18% F
Risk Adjusted Return -3.93% 43% F 23% F
Market Capitalization 0.95B 79% C+ 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -15.27 83% B 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -25.05% 34% F 25% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.59 27% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.